Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 Europe company AstraZeneca, showed significant improvements in overall survival in people with BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 year the data suggest.
Jaime Grajales Benjumea-Getty Images
The leader’s job is to make bold decisions, even when they are unusually. This is what…
In 1969, India proudly began its first Rajdan’s Express, becoming only Asia’s second country to run…
Short sellers down $180.9 billion in 2024 market losses as Wall Street surges Report Thank…
Trump raises tariffs for aluminum, steel import trade war in Salvo Report Thank you for…
Canadian Incoming Prime Stone Meets Trudove, promises fast switching Report Thank you for Report Game…
Max Tegmark, an MIT physicist who is also president of the Future of Life Institute, recently…
English